.jpg "Pluristem (NASDAQ: PSTI)")
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Pluristem (NASDAQ: PSTI), with a price target of $3.50. The company’s shares closed yesterday at $1.38.
According to TipRanks.com, Ramakanth is a 3-star analyst with an average return of 4.1% and a 37.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Eleven Biotherapeutics.
Currently, the analyst consensus on Pluristem is Moderate Buy and the average price target is $3.25, representing a 135.5% upside.
In a report issued on April 30, Maxim Group also maintained a Buy rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
Based on Pluristem’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.53 million. In comparison, last year the company had a GAAP net loss of $7.86 million.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions.
